PROJECT HELIX-HTT | Huntington’s-Adjacent Neuro-Oncology Vaccine Program | SCF Microenvironment Report (MES)

D-WS4-001

SCF Microenvironment Report (MES)

PROJECT HELIX-HTT | Huntington’s-Adjacent Neuro-Oncology Vaccine Program

DOCUMENT CONTROL HEADER

Program Code: SCF-ARGEN-HTT-NO-01

Workflow Stage: Discovery Phase

Deliverable: Core Deliverable #6

Document Code: SCF-MES-NO-0001

Purpose: Characterize the tumor microenvironment, immune accessibility, redox-hypoxia landscape, neuroimmune state, and vaccine permissibility using SCF and RHENOVA frameworks.

1. PURPOSE OF THE SCF MICROENVIRONMENT REPORT

Most cancer vaccine programs fail because they focus exclusively on the antigen while ignoring the environment in which the immune response must operate.

The SCF Microenvironment Report answers:

Can immune cells physically reach the tumor?
Can the tumor present antigens effectively?
Is the tumor suppressing immune activation?
Does the neuroimmune environment permit safe immune stimulation?
Is the terrain favorable for vaccine success?

2. SCF MICROENVIRONMENT ARCHITECTURE

Tumor Biology
       ↓
Immune Accessibility
       ↓
Antigen Presentation
       ↓
Hypoxia / Redox Mapping
       ↓
Neuroimmune Analysis
       ↓
SCF-MES Score
       ↓
Vaccine Readiness Assessment

3. MASTER MICROENVIRONMENT DOMAINS

Domain	Objective	Output
Immune Access	Determine immune infiltration	IAS
Antigen Presentation	Determine visibility	APS
Redox Biology	Determine oxidative burden	RBS
Hypoxia Biology	Determine oxygen restriction	HBS
Neuroimmune State	Determine CNS immune compatibility	NIS
Immune Suppression	Determine resistance mechanisms	ISS

4. IMMUNE ACCESSIBILITY MODULE

Objective

Measure the ability of immune cells to enter the tumor.

Core Markers

Marker	Interpretation
CD8	Cytotoxic infiltration
CD4	Helper infiltration
CXCL9	T-cell recruitment
CXCL10	T-cell recruitment
CCL5	Immune trafficking

Immune Accessibility Score (IAS)

Classification

Score	Interpretation
80–100	Highly accessible
60–79	Accessible
40–59	Limited
<40	Poor access

5. ANTIGEN PRESENTATION MODULE

Objective

Determine whether tumor cells can display antigens.

Core Markers

Marker	Function
HLA-A	Class I presentation
HLA-B	Class I presentation
HLA-C	Class I presentation
B2M	MHC stability
TAP1	Peptide transport
TAP2	Peptide transport

Antigen Presentation Score (APS)

Interpretation

Score	Meaning
>80	Excellent
60–80	Functional
40–60	Compromised
<40	Severely impaired

6. RHENOVA REDOX BIOLOGY MODULE

Objective

Quantify oxidative stress burden.

Core Biomarkers

Marker	Interpretation
8-OHdG	Oxidative DNA damage
MDA	Lipid peroxidation
GSH:GSSG	Antioxidant reserve
ROS Burden	Oxidative stress load

Redox Burden Score (RBS)

7. RHENOVA HYPOXIA MODULE

Objective

Measure oxygen-restricted tumor terrain.

Biomarkers

Marker	Function
HIF-1α	Hypoxia master regulator
CAIX	Chronic hypoxia
VEGF	Angiogenic adaptation
pO₂	Oxygen availability

Hypoxia Burden Score (HBS)

Interpretation

Score	Meaning
<25	Minimal
25–50	Moderate
50–75	Significant
>75	Severe

8. IMMUNE SUPPRESSION MODULE

Objective

Identify immune escape mechanisms.

Core Markers

Marker	Function
PD-L1	Checkpoint suppression
CTLA4	T-cell inhibition
LAG3	Exhaustion
TIGIT	Exhaustion
IDO1	Metabolic suppression

Immune Suppression Score (ISS)

9. NEUROIMMUNE STATE MODULE

Objective

Determine CNS compatibility for therapeutic vaccination.

Microglial Markers

Marker	Interpretation
IBA1	Microglial activation
TREM2	Adaptive microglia
TNF-α	Inflammatory activation
IL-1β	Neuroinflammation
CXCL10	Neuroimmune recruitment

Neuroimmune State Score (NIS)

10. SCF MICROENVIRONMENT SUITABILITY SCORE

SCF-MES

Integrated master score.

Formula:

SCF-MES =
Immune Accessibility
+
Antigen Presentation
+
Neuroimmune Compatibility

-
Hypoxia Burden
-
Redox Burden
-
Immune Suppression

11. MICROENVIRONMENT CLASSIFICATION

Class	Interpretation
MES-A	Vaccine ready
MES-B	Corrective optimization recommended
MES-C	Significant barriers present
MES-D	Not suitable for vaccine deployment

12. SCF MICROENVIRONMENT RISK MATRIX

Risk Domain	Severity	Action
Hypoxia	Low/Moderate/High	Correction strategy
Redox Instability	Low/Moderate/High	RHENOVA intervention
Immune Suppression	Low/Moderate/High	Immune conditioning
Neuroimmune Toxicity	Low/Moderate/High	Safety review

13. VACCINE READINESS ASSESSMENT

GO Criteria

✓ IAS > 60

✓ APS > 60

✓ ISS < 50

✓ NIS acceptable

✓ MES-A or MES-B

CONDITIONAL GO

✓ MES-C

✓ Correctable hypoxia

✓ Correctable immune suppression

NO-GO

✗ MES-D

✗ Severe immune escape

✗ Severe neuroimmune toxicity

✗ Antigen presentation collapse

14. MES OUTPUT FILES

MES-01

Immune Accessibility Report

MES-02

Antigen Presentation Report

MES-03

RHENOVA Redox Report

MES-04

RHENOVA Hypoxia Report

MES-05

Neuroimmune Compatibility Report

MES-06

Integrated SCF-MES Dashboard

15. INTEGRATION WITH DISCOVERY PIPELINE

Deliverable	Relationship
Mutation Catalog	Source mutations
Expression Atlas	Transcript support
HLA Matrix	Presentation prediction
Presented Antigen Library	Confirmed antigens
MES Report	Vaccine feasibility

16. DECISION GATE

Advance to Ranked Antigen Candidate Library if:

✓ SCF-MES calculated

✓ Immune barriers characterized

✓ Vaccine readiness assigned

✓ Neuroimmune safety reviewed

✓ Terrain suitability established

DELIVERABLE SUMMARY

The SCF Microenvironment Report provides:

Immune accessibility assessment
Antigen presentation competency analysis
RHENOVA redox–hypoxia mapping
Neuroimmune compatibility profiling
Vaccine readiness classification

It determines not only what antigen to target, but whether the biological terrain will permit vaccine success.

STATUS

Core Deliverable #6: COMPLETE

NEXT DELIVERABLE: Core Deliverable #7 — Ranked Antigen Candidate Library (RACL)

Reply NEXT to generate Deliverable #7.

Score	Interpretation
Balanced	Vaccine compatible
Activated	Monitor
Dysregulated	Intervention required
Hyperactivated	Safety risk

PROJECT HELIX-HTT | Huntington’s-Adjacent Neuro-Oncology Vaccine Program | SCF Microenvironment Report (MES)

D-WS4-001

SCF Microenvironment Report (MES)